Archive for: English

Diagonal Bio will present LAMPlify® at a partnered event for trainers at Jägersro

, ,
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") will be participating in a partnered event with Svensk Galopp, at Jägersro on November 7, 2024. The Company’s diagnostic platform, LAMPlify®, will be introduced to a select…

Diagonal Bio announces successful external validation of LAMPlify® for viruses in pigs

, , , ,
Diagonal Bio AB (publ) (“Diagonal” or “the Company”) announces successful results of a recent pilot study conducted by the Centre for Diagnostics at DTU Health Technology. The study evaluated the performance of the LAMPlify®…

Hunneberga Horse Stable to conduct pilot test of LAMPlify®

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that Hunneberga Horse Stable (Hunneberga Hästgård) and Tomas Hammar, showjumping trainer and CEO at Hunneberga Horse Stable, has initiated a partnership with Diagonal…

Horse trainer Daniel Redén at StallZet will conduct a pilot with LAMPlify®

, , , ,
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has partnered with StallZet and Daniel Redén, one of Sweden's leading horse trotting training facilities, to conduct a pilot test using LAMPlify® to…

Diagonal Bio AB’s warrant exercise registered at the Swedish Companies Registration Office

, , ,
Diagonal Bio AB ("Diagonal" or the "Company") today announces that the new shares from the exercise of warrants of series TO 1 have been registered with the Swedish Companies Registration Office.On 26 September 2024, the exercise period for…

Diagonal Bio AB announces the outcome of the exercise of warrants of series TO 1

, , ,
On September 26, 2024, the exercise period for Diagonal Bio AB's ("Diagonal" or the "Company") warrants of series TO 1 ("TO 1") ended. A total of 77.794 warrants of series TO 1 have been exercised to subscribe for 77.794 shares, corresponding…

The last day of trading in warrants of series TO 1 is on the 24th of September 2024

, ,
The 24th of September 2024 is the last day of trading in warrants of series TO 1, which were issued in connection with Diagonal Bio AB's ("Diagonal Bio" or the "Company") preferential rights issue of units that was carried out earlier in 2024.…

The exercise period for warrants of series TO 1 commences today

, ,
Today is the first day for the exercise of Diagonal Bio AB's ("Diagonal Bio" or "the Company") warrants of series TO 1 ("TO 1") which were issued in connection with the preferential issue of units that the Company carried out earlier this year.…

The exercise price for warrants of series TO 1 has been set to SEK 0,05 per new share

, , ,
Diagonal Bio AB ("Diagonal Bio" or "the Company") hereby announces that the exercise price for the warrants of series TO 1 (”TO 1”), which were issued in connection with the rights issue of units that the Company executed earlier…

Diagonal Bio announces successful external validation of LAMPlify® for respiratory viruses in horses

, , , ,
Diagonal Bio AB (publ) (“Diagonal Bio” and “the Company”) announces that its diagnostic tool, LAMPlify® has undergone a successful external validation in accordance with ISO 17025 standards. It is confirming that…